Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MK-2870 alone and with pembrolizumab in advanced solid tumors
jRCT2031230356Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of sacituzumab tirumotecan and pembrolizumab in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Objective response rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230356.